Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?

Over the past few years, Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE), have underperformed broader equities. However, throughout it all, they have maintained their dividend programs intact and currently boast high yields. Bristol Myers' forward yield is a healthy 4.4%, while Pfizer's is even juicier at 6.6%. Neither company is out of the woods yet, though, as both still have challenges ahead, notably patent cliffs. Which one is the safer bet today for dividend seekers? Let's find out. Image source: The Motley Fool.Bristol Myers will lose patent exclusivity for Opdivo -- a cancer medicine -- and Eliquis, an anticoagulant it co-markets with Pfizer, by the end of the decade. These two are among the company's best-selling drugs. However, Bristol Myers could overcome these obstacles. The drugmaker's newer, subcutaneous formulation of Opdivo will help attract many older patients and offset losses from biosimilar competition, as it is much easier and faster to administer while still being about as effective.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool